S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

InMed Pharmaceuticals (INM) Competitors

$0.41
0.00 (0.00%)
(As of 02/23/2024 ET)

INM vs. SXTP, ATXI, SBFM, ADIL, NEPT, CYCC, PHIO, ATNF, DRMA, and CWBR

Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include 60 Degrees Pharmaceuticals (SXTP), Avenue Therapeutics (ATXI), Sunshine Biopharma (SBFM), Adial Pharmaceuticals (ADIL), Neptune Wellness Solutions (NEPT), Cyclacel Pharmaceuticals (CYCC), Phio Pharmaceuticals (PHIO), 180 Life Sciences (ATNF), Dermata Therapeutics (DRMA), and CohBar (CWBR). These companies are all part of the "pharmaceutical preparations" industry.

InMed Pharmaceuticals vs.

InMed Pharmaceuticals (NASDAQ:INM) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

InMed Pharmaceuticals received 7 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. However, 50.00% of users gave 60 Degrees Pharmaceuticals an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
InMed PharmaceuticalsOutperform Votes
8
47.06%
Underperform Votes
9
52.94%
60 Degrees PharmaceuticalsOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than InMed Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMed Pharmaceuticals$4.14M0.60-$7.95MN/AN/A
60 Degrees Pharmaceuticals$510K3.29-$6.18MN/AN/A

0.5% of InMed Pharmaceuticals shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -115.76%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
InMed Pharmaceuticals-115.76% -54.31% -46.23%
60 Degrees Pharmaceuticals N/A N/A N/A

60 Degrees Pharmaceuticals has a consensus price target of $2.40, suggesting a potential upside of 721.64%. Given 60 Degrees Pharmaceuticals' higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than InMed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMed Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
60 Degrees Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 2 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.67 beat 60 Degrees Pharmaceuticals' score of 0.07 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
InMed Pharmaceuticals Positive
60 Degrees Pharmaceuticals Neutral

Summary

60 Degrees Pharmaceuticals beats InMed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.


Get InMed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INM vs. The Competition

MetricInMed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.47M$6.70B$5.03B$7.52B
Dividend YieldN/A2.72%2.92%3.86%
P/E RatioN/A10.83101.2616.11
Price / Sales0.60143.393,103.9555.29
Price / CashN/A18.1888.3852.42
Price / Book0.194.564.364.63
Net Income-$7.95M$156.18M$112.59M$207.21M
7 Day Performance20.32%1.07%0.86%-0.98%
1 Month Performance16.51%10.55%6.85%3.29%
1 Year Performance-71.87%1.27%8.77%3.69%

InMed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTP
60 Degrees Pharmaceuticals
2.0049 of 5 stars
$0.33
+10.2%
$2.40
+638.5%
N/A$1.89M$510,000.000.002Positive News
ATXI
Avenue Therapeutics
3.9708 of 5 stars
$0.14
flat
$32.00
+22,030.0%
-87.7%$1.92MN/A-0.242Gap Up
SBFM
Sunshine Biopharma
2.987 of 5 stars
$0.07
-63.6%
$2.60
+3,679.1%
-93.4%$1.77M$4.35M-0.0446Positive News
Gap Down
High Trading Volume
ADIL
Adial Pharmaceuticals
0 of 5 stars
$1.23
+8.8%
N/A-92.4%$2.04MN/A-0.2216Positive News
Gap Up
High Trading Volume
NEPT
Neptune Wellness Solutions
0.904 of 5 stars
$0.38
-13.8%
N/A-98.5%$1.70M$52.62M0.0058Analyst Report
News Coverage
Gap Down
High Trading Volume
CYCC
Cyclacel Pharmaceuticals
1.2674 of 5 stars
$2.50
+1.6%
$70.50
+2,720.0%
-81.7%$2.10MN/A-0.082,018News Coverage
Gap Up
PHIO
Phio Pharmaceuticals
2.3434 of 5 stars
$0.67
-2.9%
$4.00
+497.9%
-83.7%$1.63MN/A0.009News Coverage
ATNF
180 Life Sciences
0 of 5 stars
$0.21
flat
N/A-93.6%$1.59MN/A0.005Positive News
Gap Down
DRMA
Dermata Therapeutics
2.0471 of 5 stars
$0.44
flat
$4.00
+809.1%
-90.4%$1.56MN/A-0.088Positive News
Gap Down
CWBR
CohBar
0 of 5 stars
$0.76
-12.6%
N/A-57.3%$2.21MN/A-0.179Gap Up

Related Companies and Tools

This page (NASDAQ:INM) was last updated on 2/23/2024 by MarketBeat.com Staff